While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.
While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.
Former US President Jimmy Carter, who was diagnosed in August with metastatic melanoma that had spread to his brain, said...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
